Business
Result of AGM
Physiomics plc announced that all resolutions presented at its annual general meeting were passed, including the approval of accounts with 98.8% of votes for, the re-election of directors Dr. Jim Millen (94.6% for) and Dr. Tim Corn (94.5% for), and the appointment of the auditor (98.6% for). Shareholders also approved the authority to allot shares with 85.9% of votes for and the disapplication of pre-emption rights with 81.9% of votes for, indicating strong shareholder support for the company's governance and future share issuance capabilities. Disclaimer*
About this update from Physiomics Plc
18 November 2025 Physiomics plc ("Physiomics" or the "Company") Result of AGM Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biometrics company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that all resolutions put to shareholders at the Company's annual general meeting, held earlier today, were duly passed. Voting was conducted by a show of hands and inclusive of votes received by the Company by way of proxy. Details of the proxy voting results are shown in the table below. Ordinary Resolutions Votes For % Votes Against % Votes Withheld Votes Total % of ISC Voted 1 Approval of the accounts 27,842,565 98.8% 314,631 1.1% 3,461 28,160,657 9.3% 2 Re-election of Dr Jim Millen as a Director of the Company 26,622,673 94.6% 1,510,182 5.4% 27,802 28,160,657 9.3% 3 Re-election of Dr Tim Corn as a Director of the Company 26,586,162 94.5% 1,546,693 5.5% 27,802 28,160,657 9.3% 4 Appointment and renumeration of auditor 27,774,713 98.6% 375,483 1.3% 10,461 28,160,657 9.3% 5 Authority to allot shares 24,190,035 85.9% 2,007,140 7.1% 1,963,482 28,160,657 9.3% Special Resolution 6 Disapplication of shareholders' statutory pre-emption rights 23,055,357 81.9% 3,141,818 11.2% 1,963,482 28,160,657 9.3% ISC - Issued Share Capital For more information about Physiomics and its services, please visit www.physiomics.co.uk . Enquiries: Physiomics plc Dr Peter Sargent, CEO +44 (0)1235 841575 Hybridan LLP (Broker) Claire Louise Noyce +44 (0) 203 764 2341 Strand Hanson Ltd (NOMAD) James Dance & James Bellman +44 (0)20 7409 3494 Notes to Editor About Physiomics Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 140 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.